Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Xponance Inc.

Xponance Inc. grew its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 6.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 10,162 shares of the biopharmaceutical company’s stock after acquiring an additional 648 shares during the quarter. Xponance Inc.’s holdings in Ultragenyx Pharmaceutical were worth $486,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of RARE. UMB Bank n.a. lifted its holdings in Ultragenyx Pharmaceutical by 118.8% in the fourth quarter. UMB Bank n.a. now owns 606 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 329 shares during the period. Covestor Ltd raised its position in shares of Ultragenyx Pharmaceutical by 392.1% during the 3rd quarter. Covestor Ltd now owns 748 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 596 shares in the last quarter. International Assets Investment Management LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 3,182.4% in the 4th quarter. International Assets Investment Management LLC now owns 1,674 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 1,623 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Ultragenyx Pharmaceutical by 97.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 903 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Ultragenyx Pharmaceutical by 38.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,979 shares of the biopharmaceutical company’s stock valued at $95,000 after acquiring an additional 548 shares during the period. Institutional investors own 97.67% of the company’s stock.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 3,756 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, March 1st. The stock was sold at an average price of $53.76, for a total transaction of $201,922.56. Following the completion of the sale, the executive vice president now owns 67,340 shares of the company’s stock, valued at $3,620,198.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 3,756 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $53.76, for a total value of $201,922.56. Following the completion of the sale, the executive vice president now directly owns 67,340 shares of the company’s stock, valued at $3,620,198.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Thomas Richard Kassberg sold 11,509 shares of the firm’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $49.93, for a total transaction of $574,644.37. Following the transaction, the executive vice president now owns 252,823 shares in the company, valued at approximately $12,623,452.39. The disclosure for this sale can be found here. Insiders sold 32,116 shares of company stock valued at $1,645,983 in the last quarter. Company insiders own 6.80% of the company’s stock.

Ultragenyx Pharmaceutical Trading Up 0.9 %

Shares of RARE stock opened at $44.24 on Friday. Ultragenyx Pharmaceutical Inc. has a 1-year low of $31.52 and a 1-year high of $54.98. The stock’s fifty day simple moving average is $47.89 and its 200-day simple moving average is $43.75.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.65) by $0.13. The company had revenue of $127.39 million for the quarter, compared to the consensus estimate of $119.38 million. Ultragenyx Pharmaceutical had a negative return on equity of 369.54% and a negative net margin of 139.70%. The firm’s quarterly revenue was up 23.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.16) EPS. Equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. TD Cowen upped their price objective on Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the company a “buy” rating in a report on Wednesday. Royal Bank of Canada assumed coverage on shares of Ultragenyx Pharmaceutical in a report on Monday, April 22nd. They issued an “outperform” rating and a $77.00 price target for the company. Robert W. Baird lifted their price objective on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 30th. Canaccord Genuity Group increased their target price on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the company a “buy” rating in a research note on Wednesday, February 21st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $107.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, April 5th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $88.08.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.